Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00516893
Status:
COMPLETED
Last Update Posted:
2014-05-15
First Post:
2007-08-14
Brief Title:
Natalizumab High Titer Immunogenicity and Safety
Sponsor:
Biogen
Organization:
Biogen
Organization Data
Organization:
Biogen
Class:
INDUSTRY
Study ID:
101MS201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Biogen
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Biogen Idec Medical Director
Old Organization:
Biogen Idec
Collaborators
| Name | Class |
|---|---|
| Elan Pharmaceuticals | INDUSTRY |